BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
BioLife Solutions Stock Up 0.8 %
BLFS stock opened at $23.14 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -16.30 and a beta of 1.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $26.73. The firm’s 50 day moving average price is $24.64 and its 200-day moving average price is $21.72.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. On average, equities research analysts anticipate that BioLife Solutions, Inc. will post -0.36 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on BLFS
Hedge Funds Weigh In On BioLife Solutions
Several institutional investors have recently modified their holdings of BLFS. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the second quarter worth $35,000. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Register Financial Advisors LLC acquired a new position in shares of BioLife Solutions in the first quarter worth $96,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the second quarter worth $122,000. Institutional investors and hedge funds own 93.24% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Recommended Stories
- Five stocks we like better than BioLife Solutions
- Basic Materials Stocks Investing
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- Breakout Stocks: What They Are and How to Identify Them
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
- Using the MarketBeat Dividend Yield Calculator
- Insider Selling is not a Signal to Start Selling Gartner Stock
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.